SCHEMBL5152928

SCHEMBL5152928

CNCCNc1ccc(C(=O)OC)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.68
CA1 P00915 4/20 0.57
CA2 P00918 4/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
RAB9A P51151 5/20 0.55
ALDH1A1 P00352 4/20 0.55
NPC1 O15118 3/20 0.55
HPGD P15428 2/20 0.55
AGTR1 P30556 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MAPT P10636 5/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
KDM4E B2RXH2 1/20 0.50
ATM Q13315 1/20 0.50
HKDC1 Q2TB90 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CA12 O43570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25046258 0.85 POLB (0.66) POLBCA1CA2MEN1KMT2A
SCHEMBL30942687 0.84 POLB (0.66) POLBCA1CA2MEN1KMT2A
SCHEMBL5925515 0.84 POLB (0.70) POLBCA1CA2MEN1KMT2A
SCHEMBL7606973 0.84 POLB (0.70) POLBCA1CA2MEN1KMT2A
SCHEMBL5008297 0.82 POLB (0.68) POLBCA1CA2MEN1KMT2A
SCHEMBL21659729 0.82 POLB (0.68) POLBCA1CA2MEN1KMT2A
SCHEMBL7616691 0.82 POLB (0.68) POLBCA1CA2MEN1KMT2A
Hydrochloric Acid SCHEMBL28694340 0.81 POLB (0.66) POLBCA1CA2MEN1KMT2A
SCHEMBL14149520 0.81 SCN5A (0.68) POLBCA1CA2MEN1KMT2A
SCHEMBL1798924 0.79 POLB (0.64) POLBCA1CA2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 POLB 4473/4885CA1 989/4885CA2 2157/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 POLB 4449/4885CA1 1227/4885CA2 2236/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 POLB 4438/4885CA1 1030/4885CA2 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.